EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

A randomized, open‐label, 5‐period crossover study evaluating the pharmacokinetics and safety of a single dose of intranasal dihydroergotamine (DHE) powder (STS101), intramuscular DHE mesylate, and liquid nasal spray DHE in healthy adults

Richard B Lipton iD, Detlef Albrecht, Maria Bermudez, Jerry Hu, Elizabeth Hussey, Jeff Levy

Headache: The Journal of Head and Face Pain · 2024

DOI: 10.1111/head.14685 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Headache: The Journal of Head and Face Pain, 2024. Verfasst von Richard B Lipton und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology Montefiore Headache Center, Albert Einstein College of Medicine, Bronx, New York, USA. Hauptthemen laut MEDLINE: Dihydroergotamine, Mesylates, Migraine Disorders. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Satsuma Pharmaceuticals, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To compare the safety and pharmacokinetics (PK) of dihydroergotamine (DHE) after administration of intranasal DHE powder (STS101), liquid nasal spray (LNS) DHE mesylate, and intramuscular (IM) DHE mesylate injection in healthy participants.

Background

DHE is an effective acute migraine treatment; however, self‐administration difficulties have prevented its broader role in the management of migraine.

Methods

This randomized, active‐controlled, five‐period crossover study was conducted over 5 weeks separated by 1‐week washout periods. Three STS101 dosage strengths (5.2, 7.0, 8.6 mg), and one dose each of LNS DHE 2.0 mg, and IM DHE 1.0 mg, were administered to 36 healthy participants. Liquid chromatography, tandem mass spectrometry was used to determine DHE (including its 8′OH‐DHE metabolite) plasma levels and to calculate PK parameters ( C max , T max , AUC 0‐2h , AUC 0‐last , AUC 0‐inf , and t 1/2 ). Safety was evaluated by monitoring adverse events (AEs), vital signs, electrocardiograms, nasal examinations, and laboratory parameters.

Results

Thirty‐six participants (mean age 36 years; 19% Hispanic Black and 81% Hispanic White) were enrolled. DHE plasma concentrations rose rapidly after STS101 5.2, 7.0, and 8.6 mg and IM DHE injection, with mean concentrations greater than 2000 pg/mL for all STS101 dose strengths at 20 min. All STS101 dose strengths showed approximately 3‐fold higher C max , AUC 0‐2h , and AUC 0‐inf , than the LNS DHE. The mean AUC 0‐inf of STS101 7.0 and 8.6 mg were comparable to IM DHE (12,600 and 13,200 vs. 13,400 h × pg/mL). All STS101 dose strengths showed substantially lower variability (CV%) compared to LNS DHE for C max (35%–41% vs. 87%), and AUC 0‐inf (37%–46% vs. 65%). STS101 was well tolerated, and all treatment‐emergent AEs were mild and transient.

Conclusion

STS101 showed rapid absorption and was well tolerated with mild and transient treatment‐emergent AEs. Achieving effective DHE plasma concentrations within 10 min, STS101 displayed a favorable PK profile relative to the LNS with higher C max , AUC 0‐2h , and AUC 0inf , and with greater response consistency. The AUC 0‐inf was comparable to IM DHE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DihydroergotamineMesylatesMigraine DisordersAdultHumansCross-Over StudiesNasal SpraysPowders

Stichwörter der Autor:innen

DHEdihydroergotamine mesylateintranasalmigrainepharmacokinetics

Substanzen

DihydroergotamineMesylatesNasal SpraysPowders

Autor:innen und Institutionen

  • Department of Neurology Montefiore Headache Center, Albert Einstein College of Medicine, Bronx, New York, USA.
  • Satsuma Pharmaceuticals Inc., Durham, North Carolina, USA.
  • Quotient Sciences, Miami, Florida, USA.
  • Allucent, Gary, North Carolina, USA.

ORCID-Profile: Richard B Lipton

Förderung

  • Satsuma Pharmaceuticals, Inc

Zitieren

APA

Lipton, R. B., Albrecht, D., Bermudez, M., Hu, J., Hussey, E., & Levy, J. (2024). A randomized, open‐label, 5‐period crossover study evaluating the pharmacokinetics and safety of a single dose of intranasal dihydroergotamine (DHE) powder (STS101), intramuscular DHE mesylate, and liquid nasal spray DHE in healthy adults. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14685

Vancouver

Lipton RB, Albrecht D, Bermudez M, Hu J, Hussey E, Levy J. A randomized, open‐label, 5‐period crossover study evaluating the pharmacokinetics and safety of a single dose of intranasal dihydroergotamine (DHE) powder (STS101), intramuscular DHE mesylate, and liquid nasal spray DHE in healthy adults. Headache: The Journal of Head and Face Pain. 2024. doi:10.1111/head.14685

BibTeX
@article{Lipton2024,
  author = {Lipton, Richard B and Albrecht, Detlef and Bermudez, Maria and Hu, Jerry and Hussey, Elizabeth and Levy, Jeff},
  title = {A randomized, open‐label, 5‐period crossover study evaluating the pharmacokinetics and safety of a single dose of intranasal dihydroergotamine (DHE) powder (STS101), intramuscular DHE mesylate, and liquid nasal spray DHE in healthy adults},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2024},
  doi = {10.1111/head.14685}
}
Kostenlos starten →